Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines

Cisplatin is widely employed as a first-line chemotherapeutic agent for many solid tumors, including malignant pleural mesothelioma (MPM). However, its clinical use is limited by heavy side effects and acquired resistance, the latter being mainly related to enhanced DNA repair. Many clinical trials...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabano, Elisabetta, Pinton, Giulia, Balzano, Cecilia, Boumya, Sara, Osella, Domenico, Moro, Laura, Ravera, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402032/
https://www.ncbi.nlm.nih.gov/pubmed/34443328
http://dx.doi.org/10.3390/molecules26164740

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402032/
https://www.ncbi.nlm.nih.gov/pubmed/34443328
http://dx.doi.org/10.3390/molecules26164740

Ejemplares similares